Moving forward in HIV-associated cancer

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 876-880

  Gopal, Satish ^a   Achenbach, Chad J ^b   Yanik, Elizabeth L ^c   Dittmer, Dirk P ^a   Eron, Joseph J ^a   Engels, Eric A ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; ANUS CANCER; CANCER PREVENTION; CANCER SCREENING; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LIFE EXPECTANCY; NEOPLASM; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; AFRICA SOUTH OF THE SAHARA; ANUS TUMOR; ARTICLE; B CELL LYMPHOMA; EARLY DIAGNOSIS; FEMALE; MALE; MALE HOMOSEXUALITY; METHODOLOGY; PRIMARY PREVENTION; RISK FACTOR; STATISTICS; UTERINE CERVIX TUMOR; VIROLOGY;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANUS NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; NEOPLASMS; PRIMARY PREVENTION; RISK FACTORS; SARCOMA, KAPOSI; UTERINE CERVICAL NEOPLASMS;

EID: 84899636089     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.1376     Document Type: Note

References (64)

1. Centers for Disease Control (CDC): Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men: New York City and California. MMWR Morb Mortal Wkly Rep 30:305-308, 1981
2. Centers for Disease Control (CDC): Update on acquired immune deficiency syndrome (AIDS): United States. MMWR Morb Mortal Wkly Rep 31:507-508, 513-514, 1982
3. van Sighem AI, Gras LA, Reiss P, et al: Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 24:1527-1535, 2010
4. Nakagawa F, Lodwick RK, Smith CJ, et al: Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 26:335-343, 2012
5. Patel P, Hanson DL, Sullivan PS, et al: Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148:728-736, 2008 (Pubitemid 351717418)
6. Grulich AE, van Leeuwen MT, Falster MO, et al: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370:59-67, 2007 (Pubitemid 47017468)
7. Silverberg MJ, Chao C, Leyden WA, et al: HIV infection and the risk of cancers with and without a known infectious cause. AIDS 23:2337-2345, 2009
8. Engels EA, Biggar RJ, Hall HI, et al: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008 (Pubitemid 351705208)
9. Bouvard V, Baan R, Straif K, et al: A review of human carcinogens: Part B. Biological agents. Lancet Oncol 10:321-322, 2009
10. Shiels MS, Pfeiffer RM, Hall HI, et al: Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 305:1450-1459, 2011
11. Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753-762, 2011
12. Simard EP, Engels EA: Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 51:957-962, 2010
13. Bonnet F, Burty C, Lewden C, et al: Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 Survey. Clin Infect Dis 48:633-639, 2009
14. Antiretroviral Therapy Cohort Collaboration: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 50:1387-1396, 2010
15. Simard EP, Pfeiffer RM, Engels EA: Mortality due to cancer among people with AIDS: A novel approach using registry-linkage data and population attributable risk methods. AIDS 26:1311-1318, 2012
16. [No authors listed]. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41:1-19, 1992
17. Chaturvedi AK, Madeleine MM, Biggar RJ, et al: Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 101:1120-1130, 2009
18. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19, 1999 (Pubitemid 29406813)
19. De Vuyst H, Clifford GM, Nascimento MC, et al: Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int J Cancer 124:1626-1636, 2009
20. Dunleavy K, Wilson WH: How I treat HIV-associated lymphoma. Blood 119:3245-3255, 2012
21. International Agency for Research on Cancer (IARC); Swerdlow SH, Campo E, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC, 2008
22. Glaser SL, Clarke CA, Gulley ML, et al: Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 98:300-309, 2003 (Pubitemid 36828454)
23. Tirelli U, Errante D, Dolcetti R, et al: Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 13:1758-1767, 1995
24. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720, 2000 (Pubitemid 30365531)
25. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
26. Bräu N, Fox RK, Xiao P, et al: Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol 47:527-537, 2007 (Pubitemid 47334759)
27. Engels EA, Pfeiffer RM, Goedert JJ, et al: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20:1645-1654, 2006 (Pubitemid 44162407)
28. Shiels MS, Pfeiffer RM, Chaturvedi AK, et al: Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst 104:1591-1598, 2012
29. Abraham AG, D'Souza G, Jing Y, et al: Invasive cervical cancer risk among HIV-infected women: A North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 62:405-413, 2013
30. Marcucci F, Mele A: Hepatitis viruses and non-Hodgkin lymphoma: Epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 117:1792-1798, 2011
31. Engels EA, Cho ER, Jee SH: Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: A cohort study. Lancet Oncol 11:827-834, 2010
32. Giordano TP, Henderson L, Landgren O, et al: Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297:2010-2017, 2007 (Pubitemid 46740353)
33. Engels EA, Frisch M, Lubin JH, et al: Prevalence of hepatitis C virus infection and risk for hepatocellular carcinoma and non-Hodgkin lymphoma in AIDS. J Acquir Immune Defic Syndr 31:536-541, 2002 (Pubitemid 35448662)
34. Levine AM, Nelson R, Zuckerman E, et al: Lack of association between hepatitis C infection and development of AIDS-related lymphoma. J Acquir Immune Defic Syndr Hum Retrovirol 20:255-258, 1999 (Pubitemid 29156962)
35. Quon H, Forastiere AA: Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: Should we, how should we, and for whom? J Clin Oncol 31:520-522, 2013
36. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
37. Abou-Alfa GK, Venook AP: The antiangiogenic ceiling in hepatocellular carcinoma: Does it exist and has it been reached? Lancet Oncol 14:e283-e288, 2013
38. Bruix J, Raoul JL, Sherman M, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol 57:821-829, 2012
39. Huitzil FD, Saltz LS, Song J, et al: Retrospective analysis of outcome in hepatocellular carcinoma (HCC) patients (pts) with hepatitis C (C+) versus B (B+) treated with sorafenib (S). J Clin Oncol 29, 2011 (suppl; abstr e14636)
40. Barton S, Hawkes EA, Wotherspoon A, et al: Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist 17:1562-1573, 2012
41. Hill BT, Sweetenham J: Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. Leuk Lymphoma 53:763-769, 2012
42. Klein U, Gloghini A, Gaidano G, et al: Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101:4115-4121, 2003 (Pubitemid 36857893)
43. Morton LM, Kim CJ, Weiss LM, et al: Molecular characteristics of diffuse large B-cell lymphoma in human immunodeficiency virus-infected and -uninfected patients in the pre-highly active antiretroviral therapy and pre-rituximab era. Leuk Lymphoma [epub ahead of print on July 29, 2013]
44. Liapis K, Clear A, Owen A, et al: The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood 122:424-433, 2013
45. Ramos JC, Sin SH, Staudt MR, et al: Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. Int J Cancer 130:2728-2733, 2012
46. Persad GC, Little RF, Grady C: Including persons with HIV infection in cancer clinical trials. J Clin Oncol 26:1027-1032, 2008
47. National Cancer Institute: Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma. www.cancer.gov/clinicaltrials/search/view?cdrid=630501&version= HealthProfessional&protocolsearchid=8135627
48. Krown SE, Lee JY, Dittmer DP: More on HIV-associated Kaposi's sarcoma. N Engl J Med 358:535-536, 2008
49. Gopal S, Patel MR, Yanik EL, et al: Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 105:1221-1229, 2013
50. Achenbach CJ, Cole SR, Kitahata MM, et al: Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. AIDS 25:691-700, 2011
51. Yanik EL, Napravnik S, Cole SR, et al: Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis 57:756-764, 2013
52. Gopal S, Patel MR, Yanik EL, et al: Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS 27:2365-2373, 2013
53. Heard I: Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS 4:68-73, 2009
54. International Agency for Research on Cancer (IARC): IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 90: Human papillomaviruses. Lyon, France, IARC, 2007
55. Mani D, Aboulafia DM: Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin Oncol 25:518-525, 2013
56. Sigel K, Brown S, Wisnivesky Y, et al: Chest CT scan findings and implications for lung cancer screening in asymptomatic HIV infected patients. Presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 5-8, 2012 (abstr 907)
57. Firnhaber C, Wilkin T: Human papillomavirus vaccines: Where do they fit in HIV-infected individuals? Curr HIV/AIDS Rep 9:278-286, 2012
58. Cohen JI, Mocarski ES, Raab-Traub N, et al: The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31:B194-B196, 2013
59. Kanakry JA, Ambinder RF: EBV-related lymphomas: New approaches to treatment. Curr Treat Options Oncol 14:224-236, 2013
60. Gopal S, Wood WA, Lee SJ, et al: Meeting the challenge of hematologic malignancies in sub-Saharan Africa. Blood 119:5078-5087, 2012
61. Joint United Nations Program on HIV/AIDS: UNAIDS Report on the Global AIDS Epidemic, 2012. http://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf
62. de Martel C, Ferlay J, Franceschi S, et al: Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 13:607-615, 2012
63. Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, et al: Advancing cervical cancer prevention initiatives in resource-constrained settings: Insights from the Cervical Cancer Prevention Program in Zambia. PLoS Med 8:e1001032, 2011
64. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, et al: Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS 23:N1-N5, 2009